Table 3.
Baseline characteristics of patients alive and the deceased at six-month follow-up.
| Variables | Patients Alive n = 17 | Deceased n = 6 | p-Value |
|---|---|---|---|
| Selenium, µg/L | 63.3 ± 14.1 | 60.1 ± 13.5 | 0.634 |
| Ceruloplasmin, mg/dL | 49.1 ± 13.2 | 39.4 ± 10.8 | 0.127 |
| Age, years | 26.3 ± 5.9 | 26.0 ± 9.2 | 0.940 |
| NYHA class | |||
| II | 7 (41.2%) | 3 (50.0%) | 0.280 |
| III | 8 (47.1%) | 1 (16.7%) | |
| IV | 2 (11.8%) | 2 (33.3%) | |
| Systolic BP, mmHg | 112.8 ± 19.2 | 120.0 ± 32.3 | 0.525 |
| Diastolic BP, mmHg | 79.8 ± 14.6 | 91.7 ± 24.0 | 0.169 |
| Heart rate, beats/min | 107 ± 19 | 114 ± 13 | 0.379 |
| Log10 income | 4.4 ± 0.3 | 4.1 ± 0.1 | 0.003 * |
| BMI, Kg/m2 | 21.1 ± 4.9 | 21.3 ± 2.4 | 0.933 |
| Log10 creatinine | 1.86 ± 0.16 | 1.90 ± 0.15 | 0.622 |
| Hemoglobin, g/dL | 12.9 ± 1.4 | 13.0 ± 1.0 | 0.929 |
| LVEDDi, mm/m2 | 40.4 ± 5.4 | 41.4 ± 4.4 | 0.683 |
| LVEF, % | 33.3 ± 10.5 | 29.2 ± 12.8 | 0.446 |
| ARB/ACEI | 8 | 4 | 0.646 |
| Beta blockers | 1 | 1 | 0.481 |
| Spironolactone | 15 | 6 | 1.000 |
| Digoxin | 16 | 5 | 0.273 |
NYHA, New York Heart Association; BP, blood pressure; BMI, body mass index; LVEDDi, left ventricular end-diastolic dimension indexed to body surface area; LVEF, left ventricular ejection fraction; ARB, angiotensin II receptor blocker; ACEI, angiotensin converting enzyme inhibitor; * p-value statistically significant. Results are presented as means ± standard deviations, or as numbers with percentages in parentheses.